Study ID: TV44749-CNS-30096

Study Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia (SOLARIS)

Study Description: The primary objective of this study is to evaluate the efficacy of TV-44749 in adult patients with schizophrenia. A key secondary objective is to further evaluate the efficacy of TV-44749 based on additional parameters in adult patients with schizophrenia. A secondary objective is to evaluate the safety and tolerability of TV-44749 in adult patients with schizophrenia. Another secondary objective of this study is to evaluate the efficacy of TV-44749 from baseline to endpoint in Period 1 in adult patients with schizophrenia. Total study duration is up to 61 weeks, and treatment duration is up to 56 weeks, with weekly visits during the first 8 weeks and then monthly in-clinic visits with weekly calls during the remainder of the treatment period.

Participation requirements include:
- Having been diagnosed with schizophrenia for at least 1 year
- Experiencing a worsening of your schizophrenia within the last 8 weeks
* Please see complete requirements via inclusion and exclusion criteria link

Key Participation Requirements

Interventional

You may contact 1-888-483-8279 or email USMedInfo@tevapharm.com to obtain more information about study locations.